J8P.F Cinclus Pharma Holding AB (publ)

Healthcare Drug Manufacturers - Specialty & Generic Frankfurt Exchange
1.00 EUR
Close of Nov 12, 2026
0.9480 1.79
Market cap
EUR 46.7M
P/E
-
P/B
2.67x
ROE
-165.3%
Dividend yield
-
Fundamental score
-

Ratios use the latest price and the current fiscal year annualized from 2 quarters up to Jun 2026.

Is J8P.F undervalued?

Graham number

The Graham number of Cinclus Pharma Holding AB (publ) cannot be estimated reliably (it needs positive earnings and book value).

Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?

Cinclus Pharma Holding AB (publ) fundamental analysis

No fundamental analysis for Cinclus Pharma Holding AB (publ) yet.

Cinclus Pharma Holding AB (publ) stock price

Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.

About Cinclus Pharma Holding AB (publ)

Cinclus Pharma Holding AB (publ), a clinical-stage pharmaceutical company, develops small molecules for the treatment of gastric acid-related diseases in China. The company's lead product is linaprazan glurate, a potassium-competitive acid blocker that has completed Phase II clinical trial to treat gastroesophageal reflux disease. It also develops linaprazan glurate with antibiotics, which is in pre-clinical trial for the treatment of peptic ulcer bacteria Helicobacter pylor…

Full company profile